C2 Pharma, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), announced the approval of a C-DMF for digoxin, an API manufactured by our Polish manufacturing partner Nobilus Ent. This milestone comes after a challenging three-year journey, due to global disruptions caused by the Covid pandemic. The approval covers both digoxin and digoxin micronized. It supports different dosage forms i.e., oral and injectable drug product formulations. Digoxin is derived from the leaves of the Digitalis lanata plant and as a cardiac glycoside, it is commonly used in clinical practice for the treatment of mild to moderate heart failure.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!